In last trading session, Arcus Biosciences Inc. (NYSE:RCUS) saw 0.64 million shares changing hands with its beta currently measuring 0.86. Company’s recent per share price level of $35.81 trading at -$0.59 or -1.62% at ring of the bell on the day assigns it a market valuation of $2.59B. That closing price of RCUS’s stock is at a discount of -37.11% from its 52-week high price of $49.10 and is indicating a premium of 37.56% from its 52-week low price of $22.36. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.74 million shares which gives us an average trading volume of 672.78K if we extend that period to 3-months.
For Arcus Biosciences Inc. (RCUS), analysts’ consensus is at an average recommendation of a Buy while assigning it a mean rating of 1.70. Splitting up the data highlights that, out of 11 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 10 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.74 in the current quarter.
Arcus Biosciences Inc. (NYSE:RCUS) trade information
Upright in the red during last session for losing -1.62%, in the last five days RCUS remained trading in the red while hitting it’s week-highest on Tuesday, 01/11/22 when the stock touched $35.81 price level, adding 10.32% to its value on the day. Arcus Biosciences Inc.’s shares saw a change of -11.51% in year-to-date performance and have moved -4.15% in past 5-day. Arcus Biosciences Inc. (NYSE:RCUS) showed a performance of -11.62% in past 30-days. Number of shares sold short was 7.08 million shares which calculate 8.22 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $64.40 to the stock, which implies a rise of 44.39% to its current value. Analysts have been projecting $43.00 as a low price target for the stock while placing it at a high target of $100.00. It follows that stock’s current price would drop -179.25% in reaching the projected high whereas dropping to the targeted low would mean a loss of -20.08% for stock’s current value.
Arcus Biosciences Inc. (RCUS) estimates and forecasts
Statistics highlight that Arcus Biosciences Inc. is scoring comparatively lower than the scores of other players of the relevant industry. The company added 20.86% of value to its shares in past 6 months, showing an annual growth rate of -94.64% while that of industry is 7.90. Apart from that, the company came lowering its revenue forecast for fiscal year 2022. The company is estimating its revenue growth to increase by 9.80% in the current quarter and calculating 138.90% increase in the next quarter. This year revenue growth is estimated to rise 14.10% from the last financial year’s standing.
8 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $39.39 million for the same. And 4 analysts are in estimates of company making revenue of $159.35 million in the next quarter that will end on Mar 2022. Company posted $9.49 million and $9.46 million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to grow by 315.20% while estimating it to be 1,584.30% for the next quarter.
Arcus Biosciences Inc. is more likely to be releasing its next quarterly report between February 22 and February 28 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Arcus Biosciences Inc. (NYSE:RCUS)’s Major holders
Insiders are in possession of 37.33% of company’s total shares while institution are holding 64.78 percent of that, with stock having share float percentage of 103.38%. Investors also watch the number of corporate investors in a company very closely, which is 64.78% institutions for Arcus Biosciences Inc. that are currently holding shares of the company. EcoR1 Capital, LLC is the top institutional holder at RCUS for having 5.12 million shares of worth $178.62 million. And as of Sep 29, 2021, it was holding 7.29% of the company’s outstanding shares.
The second largest institutional holder is Blackrock Inc., which was holding about 4.2 million shares on Sep 29, 2021. The number of shares represents firm’s hold over 5.98% of outstanding shares, having a total worth of $146.56 million.
On the other hand, Fidelity Select Portfolios – Biotechnology and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF are the top two Mutual Funds which own company’s shares. As of Oct 30, 2021, the former fund manager was holding 3.09 million shares of worth $103.37 million or 4.40% of the total outstanding shares. The later fund manager was in possession of 1.45 million shares on Sep 29, 2021, making its stake of worth around $50.49 million in the company or a holder of 2.06% of company’s stock.